Benjamin J Cowling

Sep 19, 2024 | nature.com | Janice Z. Jia |Haogao Gu |Raghavan Varadarajan |Nisha Bhandari |Malik Peiris |Gabriel M Leung | +3 more

Correction to: Nature Communications https://doi.org/10.1038/s41467-024-47590-0, published online 13 April 2024The original version of this Article contained an error in the final paragraph of page 5, second to last sentence in that it contained incorrect p-values for Figure 3 panel d (p-value changed from p = 0.0427 to p = 0.0373) and panel e (p-value changed from p = 0.0017 to p = 0.0034).

Aug 26, 2024 | nature.com | Benjamin J Cowling

AbstractWhole virion inactivated vaccine CoronaVac (C) and Spike (S) mRNA BNT162b2 (B) vaccines differ greatly in their ability to elicit neutralizing antibodies but have somewhat comparable effectiveness in protecting from severe COVID-19. We conducted further analyses for a randomized trial (Cobovax study, NCT05057169) of third dose homologous and heterologous booster vaccination, i.e. four interventions CC-C, CC-B, BB-C and BB-B.

Jun 8, 2024 | nature.com | Benjamin J Cowling

AbstractCurrently there is a lack of randomized trial data examining the use of the antiviral nirmatrelvir/ritonavir in paediatric patients with SARS-CoV-2 infection. This target trial emulation study aims to address this gap by evaluating the use of nirmatrelvir/ritonavir in non-hospitalized paediatric patients aged 12–17 years with SARS-CoV-2 Omicron variant infection.

Jan 8, 2024 | wwwnc.cdc.gov | Oliver Eales |Michael J. Plank |Benjamin J Cowling |Benjamin P. Howden

Ibrahim  NK. Epidemiologic surveillance for controlling Covid-19 pandemic: types, challenges and implications. J Infect Public Health. 2020;13:1630–8. DOIPubMedGoogle ScholarWells  CR, Townsend  JP, Pandey  A, Moghadas  SM, Krieger  G, Singer  B, et al. Optimal COVID-19 quarantine and testing strategies. Nat Commun. 2021;12:356. DOIPubMedGoogle ScholarNguyen  T, Adnan  M, Nguyen  BP, de Ligt  J, Geoghegan  JL, Dean  R, et al.

Nov 1, 2023 | nature.com | Benjamin J Cowling

AbstractTo date there is a lack of randomized trial data examining the use of the antiviral nirmatrelvir/ritonavir in SARS-CoV-2-infected pregnant persons. This target trial emulation study aims to address this gap by evaluating the use of nirmatrelvir/ritonavir in non-hospitalized pregnant women with symptomatic SARS-CoV-2 Omicron variant infection.